Kitov Pharma (PPBT): תחזית צמיחת רווח נקי למניה לשנה הבאה

Israeli management at Purple Biotech (PPBT) maintains strict cost controls, which supports business stability. The projected 12-month forward EPS trajectory, where the latest figure stands at 82.70, is based on a virtual development model and the outsourcing of production in Europe and the US. Growth potential relies on the creation of antibodies for pancreatic cancer therapy with subsequent reimbursement through health insurance.

This indicator mathematically captures the market consensus for expected earnings per share growth, stripping the calculation model of traders' emotional fluctuations. By analyzing the trend of earnings per share growth forecasts, an investor assesses the monetization potential of the CM24 antibody and the effectiveness of the Purple Biotech (PPBT) patent perimeter in overcoming tumor resistance, while accounting for interest rate volatility risks.